

NYU9301M.PR3  
CSE30  
DEB/CSE/jwb  
12/05/95

PATENT APPLICATION  
Docket No.: NYU93-01M

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Junming Le, Jan Vileck, Peter Daddona, John  
Ghrayeb, David Knight and Scott Siegel

Serial No.: 08/192,102

Group: 1806

Filed: February 4, 1994

Examiner: M. Nisbet

For: ANTI-TNF ANTIBODIES AND PEPTIDES OF HUMAN  
TUMOR NECROSIS FACTOR

**CERTIFICATE OF FACSIMILE TRANSMISSION**  
I hereby certify that this correspondence is being facsimile  
transmitted to the United States Patent and Trademark Office:  
on 12/5/95 Judy Breen  
Date Signature  
Judy Breen  
Typed or printed name of person signing certificate

*pre in/c*

**RECEIVED**  
**DEC 6 1995**  
**GROUP 1800**

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Please amend the claims as follows:  
Cancel Claims 71-90 and add new Claims 91-97 therefor.

91. A method of treating Crohn's disease in a human  
comprising administering to the human an effective  
TNF-inhibiting amount of an anti-TNF chimeric  
antibody, wherein said anti-TNF chimeric antibody

*Q1  
D2*

-2-

[D27] comprises a non-human variable region or a TNF-binding portion thereof and a human constant region.

92. The method of Claim 91 wherein the non-human variable region is of murine origin.

93. The method of Claim 91 wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to a monoclonal antibody selected from the group consisting of A2 or cA2.

94. The method of Claim 91 wherein said anti-TNF chimeric antibody does not bind to one or more epitopes included in amino acids 11-13, 37-42, 4957 or 155-157 of SEQ ID NO.: 1 of hTNF.

95. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to a monoclonal antibody selected from the group consisting of A2 or cA2.

96. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody binds to amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF.

Koo